Global Neuropathy Pain Treatment
Global Neuropathy Pain Treatment

Neuropathy Pain Treatment Comprehensive Study by Type (Peripheral Neuropathy, Entrapment Neuropathy, Post Traumatic Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Phantom Limb Pain, Others), Indication Type (Diabetic Neuropathy, Trigeminal Neuralgia, Post-herpetic Neuralgia, Chemotherapy-induced Peripheral Neuropathy, Others.), Treatment (Medication, Multimodal Therapy), Distribution Channels (Pharmacies, Retail Pharmacies, Online Pharmacies), End-user (Hospitals, Clinics, Research Organizations), Diagnosis (Imaging, Blood Tests) Players and Region - Global Market Outlook to 2024

Neuropathy Pain Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Feb 2019 Edition 248 Pages 200 Tables & Figures
Sample Report Speak with Analyst Request Discount
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
Neuropathy pain treatment involves cure of pain associated with somatosensory nervous system. As of 2018 data, 18% of Canadian population, 7% of French and over 4% of United Kingdom population experience pain of neuropathic origin. With growing geriatric population across the world, the number of neuropathic pain causing diseases will increase significantly, thus, giving pain treatment services offering companies an opportunity to explore in untapped market.

Market Drivers
  • Rising Geriatrics Population Across the World
  • Growing Number of Cancer and Diabetes Cases

Market Trend
  • Increasing Demand of Generic Drugs
  • Emergence of Innovative Pain Treatment Methods Such as Use of Electrical Stimulation Devices, Stem Cell Procedures and Others

Restraints
  • High Cost of Neuropathy Pain Treatment
  • Lack of Health Infrastructure and Budgets in Emerging Countries


The key Players profiled in the report are Pfizer [United States], Depomed [United States], Eli Lilly [United States], Endo [Ireland], Grünenthal Group [Germany], Arbor Pharmaceuticals [United States], Astellas Pharma Inc. [Japan], Biogen Inc. [United States], Baxter Healthcare Corporation [United States], Sanofi S.A [France], Abbott Laboratories [United States], AstraZeneca [United Kingdom], Johnson & Johnson Services Inc. [United States], GlaxoSmithKline plc [United Kingdom] and Depomed Inc. [United States]. Additionally, other players that are part of this comprehensive study are Biogen [United States], Centrexion Therapeutics [United States], Cerecor [United States], ContraVir Pharmaceuticals [United States], Crescita Therapeutics [Canada], DAEWOONG [South Korea], Daiichi Sankyo [Japan], Dr. Reddy's Laboratories [India], Grünenthal [Germany], GlaxoSmithKline [United Kingdom] and Hydra Biosciences [United States].

Report Objectives / Segmentation Covered
By Type
  • Peripheral Neuropathy
  • Entrapment Neuropathy
  • Post Traumatic Neuropathy
  • Trigeminal Neuralgia
  • Post Herpetic Neuralgia (PHN)
  • Phantom Limb Pain
  • Others
By Indication Type
  • Diabetic Neuropathy
  • Trigeminal Neuralgia
  • Post-herpetic Neuralgia
  • Chemotherapy-induced Peripheral Neuropathy
  • Others.

By Treatment
  • Medication
  • Multimodal Therapy

By Distribution Channels
  • Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End-user
  • Hospitals
  • Clinics
  • Research Organizations

By Diagnosis
  • Imaging
  • Blood Tests

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Geriatrics Population Across the World
      • 3.2.2. Growing Number of Cancer and Diabetes Cases
    • 3.3. Market Challenges
      • 3.3.1. Potential Adverse Effect on Health of Certain Neuropathy Pain Treatment Drugs
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand of Generic Drugs
      • 3.4.2. Emergence of Innovative Pain Treatment Methods Such as Use of Electrical Stimulation Devices, Stem Cell Procedures and Others
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neuropathy Pain Treatment, by Type, Indication Type, Treatment, Distribution Channels, End-user, Diagnosis and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Neuropathy Pain Treatment (Value)
      • 5.2.1. Global Neuropathy Pain Treatment by: Type (Value)
        • 5.2.1.1. Peripheral Neuropathy
        • 5.2.1.2. Entrapment Neuropathy
        • 5.2.1.3. Post Traumatic Neuropathy
        • 5.2.1.4. Trigeminal Neuralgia
        • 5.2.1.5. Post Herpetic Neuralgia (PHN)
        • 5.2.1.6. Phantom Limb Pain
        • 5.2.1.7. Others
      • 5.2.2. Global Neuropathy Pain Treatment by: Indication Type (Value)
        • 5.2.2.1. Diabetic Neuropathy
        • 5.2.2.2. Trigeminal Neuralgia
        • 5.2.2.3. Post-herpetic Neuralgia
        • 5.2.2.4. Chemotherapy-induced Peripheral Neuropathy
        • 5.2.2.5. Others.
      • 5.2.3. Global Neuropathy Pain Treatment by: Treatment (Value)
        • 5.2.3.1. Medication
        • 5.2.3.2. Multimodal Therapy
      • 5.2.4. Global Neuropathy Pain Treatment by: Distribution Channels (Value)
        • 5.2.4.1. Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Neuropathy Pain Treatment by: End-user (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Clinics
        • 5.2.5.3. Research Organizations
      • 5.2.6. Global Neuropathy Pain Treatment by: Diagnosis (Value)
        • 5.2.6.1. Imaging
        • 5.2.6.2. Blood Tests
      • 5.2.7. Global Neuropathy Pain Treatment Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Neuropathy Pain Treatment (Price)
      • 5.3.1. Global Neuropathy Pain Treatment by: Type (Price)
  • 6. Neuropathy Pain Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer [United States]
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Depomed [United States]
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly [United States]
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Endo [Ireland]
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Grünenthal Group [Germany]
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Arbor Pharmaceuticals [United States]
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astellas Pharma Inc. [Japan]
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biogen Inc. [United States]
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Baxter Healthcare Corporation [United States]
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi S.A [France]
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Abbott Laboratories [United States]
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. AstraZeneca [United Kingdom]
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Johnson & Johnson Services Inc. [United States]
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. GlaxoSmithKline plc [United Kingdom]
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Depomed Inc. [United States]
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Neuropathy Pain Treatment Sale, by Type, Indication Type, Treatment, Distribution Channels, End-user, Diagnosis and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Neuropathy Pain Treatment (Value)
      • 7.2.1. Global Neuropathy Pain Treatment by: Type (Value)
        • 7.2.1.1. Peripheral Neuropathy
        • 7.2.1.2. Entrapment Neuropathy
        • 7.2.1.3. Post Traumatic Neuropathy
        • 7.2.1.4. Trigeminal Neuralgia
        • 7.2.1.5. Post Herpetic Neuralgia (PHN)
        • 7.2.1.6. Phantom Limb Pain
        • 7.2.1.7. Others
      • 7.2.2. Global Neuropathy Pain Treatment by: Indication Type (Value)
        • 7.2.2.1. Diabetic Neuropathy
        • 7.2.2.2. Trigeminal Neuralgia
        • 7.2.2.3. Post-herpetic Neuralgia
        • 7.2.2.4. Chemotherapy-induced Peripheral Neuropathy
        • 7.2.2.5. Others.
      • 7.2.3. Global Neuropathy Pain Treatment by: Treatment (Value)
        • 7.2.3.1. Medication
        • 7.2.3.2. Multimodal Therapy
      • 7.2.4. Global Neuropathy Pain Treatment by: Distribution Channels (Value)
        • 7.2.4.1. Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Neuropathy Pain Treatment by: End-user (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Clinics
        • 7.2.5.3. Research Organizations
      • 7.2.6. Global Neuropathy Pain Treatment by: Diagnosis (Value)
        • 7.2.6.1. Imaging
        • 7.2.6.2. Blood Tests
      • 7.2.7. Global Neuropathy Pain Treatment Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Neuropathy Pain Treatment (Price)
      • 7.3.1. Global Neuropathy Pain Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neuropathy Pain Treatment: by Type(USD Million)
  • Table 2. Neuropathy Pain Treatment Peripheral Neuropathy , by Region USD Million (2013-2018)
  • Table 3. Neuropathy Pain Treatment Entrapment Neuropathy , by Region USD Million (2013-2018)
  • Table 4. Neuropathy Pain Treatment Post Traumatic Neuropathy , by Region USD Million (2013-2018)
  • Table 5. Neuropathy Pain Treatment Trigeminal Neuralgia , by Region USD Million (2013-2018)
  • Table 6. Neuropathy Pain Treatment Post Herpetic Neuralgia (PHN) , by Region USD Million (2013-2018)
  • Table 7. Neuropathy Pain Treatment Phantom Limb Pain , by Region USD Million (2013-2018)
  • Table 8. Neuropathy Pain Treatment Others , by Region USD Million (2013-2018)
  • Table 9. Neuropathy Pain Treatment: by Indication Type(USD Million)
  • Table 10. Neuropathy Pain Treatment Diabetic Neuropathy , by Region USD Million (2013-2018)
  • Table 11. Neuropathy Pain Treatment Trigeminal Neuralgia , by Region USD Million (2013-2018)
  • Table 12. Neuropathy Pain Treatment Post-herpetic Neuralgia , by Region USD Million (2013-2018)
  • Table 13. Neuropathy Pain Treatment Chemotherapy-induced Peripheral Neuropathy , by Region USD Million (2013-2018)
  • Table 14. Neuropathy Pain Treatment Others. , by Region USD Million (2013-2018)
  • Table 15. Neuropathy Pain Treatment: by Treatment(USD Million)
  • Table 16. Neuropathy Pain Treatment Medication , by Region USD Million (2013-2018)
  • Table 17. Neuropathy Pain Treatment Multimodal Therapy , by Region USD Million (2013-2018)
  • Table 18. Neuropathy Pain Treatment: by Distribution Channels(USD Million)
  • Table 19. Neuropathy Pain Treatment Pharmacies , by Region USD Million (2013-2018)
  • Table 20. Neuropathy Pain Treatment Retail Pharmacies , by Region USD Million (2013-2018)
  • Table 21. Neuropathy Pain Treatment Online Pharmacies , by Region USD Million (2013-2018)
  • Table 22. Neuropathy Pain Treatment: by End-user(USD Million)
  • Table 23. Neuropathy Pain Treatment Hospitals , by Region USD Million (2013-2018)
  • Table 24. Neuropathy Pain Treatment Clinics , by Region USD Million (2013-2018)
  • Table 25. Neuropathy Pain Treatment Research Organizations , by Region USD Million (2013-2018)
  • Table 26. Neuropathy Pain Treatment: by Diagnosis(USD Million)
  • Table 27. Neuropathy Pain Treatment Imaging , by Region USD Million (2013-2018)
  • Table 28. Neuropathy Pain Treatment Blood Tests , by Region USD Million (2013-2018)
  • Table 29. South America Neuropathy Pain Treatment, by Country USD Million (2013-2018)
  • Table 30. South America Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 31. South America Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 32. South America Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 33. South America Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 34. South America Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 35. South America Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 36. Brazil Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 37. Brazil Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 38. Brazil Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 39. Brazil Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 40. Brazil Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 41. Brazil Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 42. Argentina Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 43. Argentina Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 44. Argentina Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 45. Argentina Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 46. Argentina Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 47. Argentina Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 48. Rest of South America Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 49. Rest of South America Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 50. Rest of South America Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 51. Rest of South America Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 52. Rest of South America Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 53. Rest of South America Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 54. Asia Pacific Neuropathy Pain Treatment, by Country USD Million (2013-2018)
  • Table 55. Asia Pacific Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 56. Asia Pacific Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 57. Asia Pacific Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 58. Asia Pacific Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 59. Asia Pacific Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 60. Asia Pacific Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 61. China Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 62. China Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 63. China Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 64. China Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 65. China Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 66. China Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 67. Japan Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 68. Japan Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 69. Japan Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 70. Japan Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 71. Japan Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 72. Japan Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 73. India Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 74. India Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 75. India Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 76. India Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 77. India Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 78. India Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 79. South Korea Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 80. South Korea Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 81. South Korea Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 82. South Korea Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 83. South Korea Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 84. South Korea Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 85. Taiwan Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 86. Taiwan Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 87. Taiwan Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 88. Taiwan Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 89. Taiwan Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 90. Taiwan Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 91. Australia Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 92. Australia Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 93. Australia Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 94. Australia Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 95. Australia Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 96. Australia Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 97. Rest of Asia-Pacific Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 98. Rest of Asia-Pacific Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 99. Rest of Asia-Pacific Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 100. Rest of Asia-Pacific Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 101. Rest of Asia-Pacific Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 102. Rest of Asia-Pacific Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 103. Europe Neuropathy Pain Treatment, by Country USD Million (2013-2018)
  • Table 104. Europe Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 105. Europe Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 106. Europe Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 107. Europe Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 108. Europe Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 109. Europe Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 110. Germany Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 111. Germany Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 112. Germany Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 113. Germany Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 114. Germany Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 115. Germany Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 116. France Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 117. France Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 118. France Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 119. France Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 120. France Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 121. France Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 122. Italy Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 123. Italy Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 124. Italy Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 125. Italy Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 126. Italy Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 127. Italy Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 128. United Kingdom Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 129. United Kingdom Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 130. United Kingdom Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 131. United Kingdom Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 132. United Kingdom Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 133. United Kingdom Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 134. Netherlands Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 135. Netherlands Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 136. Netherlands Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 137. Netherlands Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 138. Netherlands Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 139. Netherlands Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 140. Rest of Europe Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 141. Rest of Europe Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 142. Rest of Europe Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 143. Rest of Europe Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 144. Rest of Europe Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 145. Rest of Europe Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 146. MEA Neuropathy Pain Treatment, by Country USD Million (2013-2018)
  • Table 147. MEA Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 148. MEA Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 149. MEA Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 150. MEA Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 151. MEA Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 152. MEA Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 153. Middle East Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 154. Middle East Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 155. Middle East Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 156. Middle East Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 157. Middle East Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 158. Middle East Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 159. Africa Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 160. Africa Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 161. Africa Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 162. Africa Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 163. Africa Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 164. Africa Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 165. North America Neuropathy Pain Treatment, by Country USD Million (2013-2018)
  • Table 166. North America Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 167. North America Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 168. North America Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 169. North America Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 170. North America Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 171. North America Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 172. United States Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 173. United States Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 174. United States Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 175. United States Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 176. United States Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 177. United States Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 178. Canada Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 179. Canada Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 180. Canada Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 181. Canada Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 182. Canada Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 183. Canada Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 184. Mexico Neuropathy Pain Treatment, by Type USD Million (2013-2018)
  • Table 185. Mexico Neuropathy Pain Treatment, by Indication Type USD Million (2013-2018)
  • Table 186. Mexico Neuropathy Pain Treatment, by Treatment USD Million (2013-2018)
  • Table 187. Mexico Neuropathy Pain Treatment, by Distribution Channels USD Million (2013-2018)
  • Table 188. Mexico Neuropathy Pain Treatment, by End-user USD Million (2013-2018)
  • Table 189. Mexico Neuropathy Pain Treatment, by Diagnosis USD Million (2013-2018)
  • Table 190. Neuropathy Pain Treatment: by Type(USD/Units)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Neuropathy Pain Treatment: by Type(USD Million)
  • Table 207. Neuropathy Pain Treatment Peripheral Neuropathy , by Region USD Million (2019-2024)
  • Table 208. Neuropathy Pain Treatment Entrapment Neuropathy , by Region USD Million (2019-2024)
  • Table 209. Neuropathy Pain Treatment Post Traumatic Neuropathy , by Region USD Million (2019-2024)
  • Table 210. Neuropathy Pain Treatment Trigeminal Neuralgia , by Region USD Million (2019-2024)
  • Table 211. Neuropathy Pain Treatment Post Herpetic Neuralgia (PHN) , by Region USD Million (2019-2024)
  • Table 212. Neuropathy Pain Treatment Phantom Limb Pain , by Region USD Million (2019-2024)
  • Table 213. Neuropathy Pain Treatment Others , by Region USD Million (2019-2024)
  • Table 214. Neuropathy Pain Treatment: by Indication Type(USD Million)
  • Table 215. Neuropathy Pain Treatment Diabetic Neuropathy , by Region USD Million (2019-2024)
  • Table 216. Neuropathy Pain Treatment Trigeminal Neuralgia , by Region USD Million (2019-2024)
  • Table 217. Neuropathy Pain Treatment Post-herpetic Neuralgia , by Region USD Million (2019-2024)
  • Table 218. Neuropathy Pain Treatment Chemotherapy-induced Peripheral Neuropathy , by Region USD Million (2019-2024)
  • Table 219. Neuropathy Pain Treatment Others. , by Region USD Million (2019-2024)
  • Table 220. Neuropathy Pain Treatment: by Treatment(USD Million)
  • Table 221. Neuropathy Pain Treatment Medication , by Region USD Million (2019-2024)
  • Table 222. Neuropathy Pain Treatment Multimodal Therapy , by Region USD Million (2019-2024)
  • Table 223. Neuropathy Pain Treatment: by Distribution Channels(USD Million)
  • Table 224. Neuropathy Pain Treatment Pharmacies , by Region USD Million (2019-2024)
  • Table 225. Neuropathy Pain Treatment Retail Pharmacies , by Region USD Million (2019-2024)
  • Table 226. Neuropathy Pain Treatment Online Pharmacies , by Region USD Million (2019-2024)
  • Table 227. Neuropathy Pain Treatment: by End-user(USD Million)
  • Table 228. Neuropathy Pain Treatment Hospitals , by Region USD Million (2019-2024)
  • Table 229. Neuropathy Pain Treatment Clinics , by Region USD Million (2019-2024)
  • Table 230. Neuropathy Pain Treatment Research Organizations , by Region USD Million (2019-2024)
  • Table 231. Neuropathy Pain Treatment: by Diagnosis(USD Million)
  • Table 232. Neuropathy Pain Treatment Imaging , by Region USD Million (2019-2024)
  • Table 233. Neuropathy Pain Treatment Blood Tests , by Region USD Million (2019-2024)
  • Table 234. South America Neuropathy Pain Treatment, by Country USD Million (2019-2024)
  • Table 235. South America Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 236. South America Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 237. South America Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 238. South America Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 239. South America Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 240. South America Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 241. Brazil Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 242. Brazil Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 243. Brazil Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 244. Brazil Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 245. Brazil Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 246. Brazil Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 247. Argentina Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 248. Argentina Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 249. Argentina Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 250. Argentina Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 251. Argentina Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 252. Argentina Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 253. Rest of South America Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 254. Rest of South America Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 255. Rest of South America Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 256. Rest of South America Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 257. Rest of South America Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 258. Rest of South America Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 259. Asia Pacific Neuropathy Pain Treatment, by Country USD Million (2019-2024)
  • Table 260. Asia Pacific Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 261. Asia Pacific Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 262. Asia Pacific Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 263. Asia Pacific Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 264. Asia Pacific Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 265. Asia Pacific Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 266. China Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 267. China Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 268. China Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 269. China Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 270. China Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 271. China Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 272. Japan Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 273. Japan Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 274. Japan Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 275. Japan Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 276. Japan Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 277. Japan Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 278. India Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 279. India Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 280. India Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 281. India Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 282. India Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 283. India Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 284. South Korea Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 285. South Korea Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 286. South Korea Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 287. South Korea Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 288. South Korea Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 289. South Korea Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 290. Taiwan Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 291. Taiwan Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 292. Taiwan Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 293. Taiwan Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 294. Taiwan Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 295. Taiwan Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 296. Australia Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 297. Australia Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 298. Australia Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 299. Australia Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 300. Australia Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 301. Australia Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 302. Rest of Asia-Pacific Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 303. Rest of Asia-Pacific Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 304. Rest of Asia-Pacific Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 305. Rest of Asia-Pacific Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 306. Rest of Asia-Pacific Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 307. Rest of Asia-Pacific Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 308. Europe Neuropathy Pain Treatment, by Country USD Million (2019-2024)
  • Table 309. Europe Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 310. Europe Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 311. Europe Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 312. Europe Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 313. Europe Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 314. Europe Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 315. Germany Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 316. Germany Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 317. Germany Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 318. Germany Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 319. Germany Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 320. Germany Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 321. France Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 322. France Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 323. France Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 324. France Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 325. France Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 326. France Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 327. Italy Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 328. Italy Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 329. Italy Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 330. Italy Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 331. Italy Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 332. Italy Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 333. United Kingdom Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 334. United Kingdom Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 335. United Kingdom Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 336. United Kingdom Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 337. United Kingdom Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 338. United Kingdom Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 339. Netherlands Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 340. Netherlands Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 341. Netherlands Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 342. Netherlands Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 343. Netherlands Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 344. Netherlands Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 345. Rest of Europe Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 346. Rest of Europe Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 347. Rest of Europe Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 348. Rest of Europe Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 349. Rest of Europe Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 350. Rest of Europe Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 351. MEA Neuropathy Pain Treatment, by Country USD Million (2019-2024)
  • Table 352. MEA Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 353. MEA Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 354. MEA Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 355. MEA Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 356. MEA Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 357. MEA Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 358. Middle East Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 359. Middle East Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 360. Middle East Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 361. Middle East Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 362. Middle East Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 363. Middle East Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 364. Africa Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 365. Africa Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 366. Africa Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 367. Africa Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 368. Africa Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 369. Africa Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 370. North America Neuropathy Pain Treatment, by Country USD Million (2019-2024)
  • Table 371. North America Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 372. North America Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 373. North America Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 374. North America Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 375. North America Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 376. North America Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 377. United States Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 378. United States Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 379. United States Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 380. United States Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 381. United States Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 382. United States Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 383. Canada Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 384. Canada Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 385. Canada Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 386. Canada Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 387. Canada Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 388. Canada Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 389. Mexico Neuropathy Pain Treatment, by Type USD Million (2019-2024)
  • Table 390. Mexico Neuropathy Pain Treatment, by Indication Type USD Million (2019-2024)
  • Table 391. Mexico Neuropathy Pain Treatment, by Treatment USD Million (2019-2024)
  • Table 392. Mexico Neuropathy Pain Treatment, by Distribution Channels USD Million (2019-2024)
  • Table 393. Mexico Neuropathy Pain Treatment, by End-user USD Million (2019-2024)
  • Table 394. Mexico Neuropathy Pain Treatment, by Diagnosis USD Million (2019-2024)
  • Table 395. Neuropathy Pain Treatment: by Type(USD/Units)
  • Table 396. Research Programs/Design for This Report
  • Table 397. Key Data Information from Secondary Sources
  • Table 398. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neuropathy Pain Treatment: by Type USD Million (2013-2018)
  • Figure 5. Global Neuropathy Pain Treatment: by Indication Type USD Million (2013-2018)
  • Figure 6. Global Neuropathy Pain Treatment: by Treatment USD Million (2013-2018)
  • Figure 7. Global Neuropathy Pain Treatment: by Distribution Channels USD Million (2013-2018)
  • Figure 8. Global Neuropathy Pain Treatment: by End-user USD Million (2013-2018)
  • Figure 9. Global Neuropathy Pain Treatment: by Diagnosis USD Million (2013-2018)
  • Figure 10. South America Neuropathy Pain Treatment Share (%), by Country
  • Figure 11. Asia Pacific Neuropathy Pain Treatment Share (%), by Country
  • Figure 12. Europe Neuropathy Pain Treatment Share (%), by Country
  • Figure 13. MEA Neuropathy Pain Treatment Share (%), by Country
  • Figure 14. North America Neuropathy Pain Treatment Share (%), by Country
  • Figure 15. Global Neuropathy Pain Treatment: by Type USD/Units (2013-2018)
  • Figure 16. Global Neuropathy Pain Treatment share by Players 2018 (%)
  • Figure 17. Global Neuropathy Pain Treatment share by Players (Top 3) 2018(%)
  • Figure 18. Global Neuropathy Pain Treatment share by Players (Top 5) 2018(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. Pfizer [United States] Revenue, Net Income and Gross profit
  • Figure 21. Pfizer [United States] Revenue: by Geography 2018
  • Figure 22. Depomed [United States] Revenue, Net Income and Gross profit
  • Figure 23. Depomed [United States] Revenue: by Geography 2018
  • Figure 24. Eli Lilly [United States] Revenue, Net Income and Gross profit
  • Figure 25. Eli Lilly [United States] Revenue: by Geography 2018
  • Figure 26. Endo [Ireland] Revenue, Net Income and Gross profit
  • Figure 27. Endo [Ireland] Revenue: by Geography 2018
  • Figure 28. Grünenthal Group [Germany] Revenue, Net Income and Gross profit
  • Figure 29. Grünenthal Group [Germany] Revenue: by Geography 2018
  • Figure 30. Arbor Pharmaceuticals [United States] Revenue, Net Income and Gross profit
  • Figure 31. Arbor Pharmaceuticals [United States] Revenue: by Geography 2018
  • Figure 32. Astellas Pharma Inc. [Japan] Revenue, Net Income and Gross profit
  • Figure 33. Astellas Pharma Inc. [Japan] Revenue: by Geography 2018
  • Figure 34. Biogen Inc. [United States] Revenue, Net Income and Gross profit
  • Figure 35. Biogen Inc. [United States] Revenue: by Geography 2018
  • Figure 36. Baxter Healthcare Corporation [United States] Revenue, Net Income and Gross profit
  • Figure 37. Baxter Healthcare Corporation [United States] Revenue: by Geography 2018
  • Figure 38. Sanofi S.A [France] Revenue, Net Income and Gross profit
  • Figure 39. Sanofi S.A [France] Revenue: by Geography 2018
  • Figure 40. Abbott Laboratories [United States] Revenue, Net Income and Gross profit
  • Figure 41. Abbott Laboratories [United States] Revenue: by Geography 2018
  • Figure 42. AstraZeneca [United Kingdom] Revenue, Net Income and Gross profit
  • Figure 43. AstraZeneca [United Kingdom] Revenue: by Geography 2018
  • Figure 44. Johnson & Johnson Services Inc. [United States] Revenue, Net Income and Gross profit
  • Figure 45. Johnson & Johnson Services Inc. [United States] Revenue: by Geography 2018
  • Figure 46. GlaxoSmithKline plc [United Kingdom] Revenue, Net Income and Gross profit
  • Figure 47. GlaxoSmithKline plc [United Kingdom] Revenue: by Geography 2018
  • Figure 48. Depomed Inc. [United States] Revenue, Net Income and Gross profit
  • Figure 49. Depomed Inc. [United States] Revenue: by Geography 2018
  • Figure 50. Global Neuropathy Pain Treatment: by Type USD Million (2019-2024)
  • Figure 51. Global Neuropathy Pain Treatment: by Indication Type USD Million (2019-2024)
  • Figure 52. Global Neuropathy Pain Treatment: by Treatment USD Million (2019-2024)
  • Figure 53. Global Neuropathy Pain Treatment: by Distribution Channels USD Million (2019-2024)
  • Figure 54. Global Neuropathy Pain Treatment: by End-user USD Million (2019-2024)
  • Figure 55. Global Neuropathy Pain Treatment: by Diagnosis USD Million (2019-2024)
  • Figure 56. South America Neuropathy Pain Treatment Share (%), by Country
  • Figure 57. Asia Pacific Neuropathy Pain Treatment Share (%), by Country
  • Figure 58. Europe Neuropathy Pain Treatment Share (%), by Country
  • Figure 59. MEA Neuropathy Pain Treatment Share (%), by Country
  • Figure 60. North America Neuropathy Pain Treatment Share (%), by Country
  • Figure 61. Global Neuropathy Pain Treatment: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Pfizer [United States]
  • Depomed [United States]
  • Eli Lilly [United States]
  • Endo [Ireland]
  • Grünenthal Group [Germany]
  • Arbor Pharmaceuticals [United States]
  • Astellas Pharma Inc. [Japan]
  • Biogen Inc. [United States]
  • Baxter Healthcare Corporation [United States]
  • Sanofi S.A [France]
  • Abbott Laboratories [United States]
  • AstraZeneca [United Kingdom]
  • Johnson & Johnson Services Inc. [United States]
  • GlaxoSmithKline plc [United Kingdom]
  • Depomed Inc. [United States]
Additional players considered in the study are as follows:
Biogen [United States] , Centrexion Therapeutics [United States] , Cerecor [United States] , ContraVir Pharmaceuticals [United States] , Crescita Therapeutics [Canada] , DAEWOONG [South Korea] , Daiichi Sankyo [Japan] , Dr. Reddy's Laboratories [India] , Grünenthal [Germany] , GlaxoSmithKline [United Kingdom] , Hydra Biosciences [United States]
Select License Type
Sample Report Enquiry Before Buy Request Discount
Slider
Slider
Slider
DOWNLOAD SAMPLE PDF

Speak with Analyst

Want to find out more about this report?

Get Free Consultation
Ask a Question!

Related Reports

Vitamin Deficiency Treatment Comprehensive Study by Type (Multivitamin Deficiency Treatment, Single Vitamin Deficiency Treatment), End Users (Adults, Kids), Route of Administration (Oral, Parenteral)...
Vitamin Deficiency Treatment Comprehensive Study by Type (Multivitamin Deficiency Treatment, Single Vitamin Deficiency Treatment), End Users (Adults, Kids), Route of Administration (Oral, Parenteral)...
$ 3800
Bronchitis Treatment Comprehensive Study by Type (Acute Bronchitis, Chronic Bronchitis), Treatment (Drugs, Oxygen Therapy), Drugs Class (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Other), ...
Bronchitis Treatment Comprehensive Study by Type (Acute Bronchitis, Chronic Bronchitis), Treatment (Drugs, Oxygen Therapy), Drugs Class (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Other), ...
$ 4000
Parkinson's Disease Treatment Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), Patient Care Setting (Hospitals, Clinics), Drug Class (Carbido...
Parkinson's Disease Treatment Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies), Patient Care Setting (Hospitals, Clinics), Drug Class (Carbido...
$ 3800
Mantle Cell Lymphoma Treatment Comprehensive Study by Type (Acalabrutinib, JCAR-017, JNJ-64052781, Acalisib, IGN-002, IMGN-529, AFM-11, Others), Application (Hospital, Clinic, Others), Route of Admin...
Mantle Cell Lymphoma Treatment Comprehensive Study by Type (Acalabrutinib, JCAR-017, JNJ-64052781, Acalisib, IGN-002, IMGN-529, AFM-11, Others), Application (Hospital, Clinic, Others), Route of Admin...
$ 3800
Non-alcoholic Steatohepatitis Comprehensive Study by Type (Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, Others), Application (Hypertension, Heart Disease, High Blood Lipid, Diabetes, Obesity), En...
Non-alcoholic Steatohepatitis Comprehensive Study by Type (Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, Others), Application (Hypertension, Heart Disease, High Blood Lipid, Diabetes, Obesity), En...
$ 3800
Ophthalmology Drugs Comprehensive Study by Type (Lucentis (Ranibizumab), Eylea (Aflibercept), Avastin (Bevacizumab), Restasis (Cyclosporine), Alphagan (Brimonidine Tartrate), Lumigan (Bimatoprost), X...
Ophthalmology Drugs Comprehensive Study by Type (Lucentis (Ranibizumab), Eylea (Aflibercept), Avastin (Bevacizumab), Restasis (Cyclosporine), Alphagan (Brimonidine Tartrate), Lumigan (Bimatoprost), X...
$ 3800